PSA as the driving biomarker to manage low-and intermediate-risk prostate cancer patients in clinical practice  

作　　者：Enrico Ricevuto Celeste Morgani Fabrizia Seri Gemma Bruera 

机构地区：[1]Oncology Territorial Care Unit,S.Salvatore Hospital,University of L’Aquila,L’Aquila 67100,Italy [2]Department of Biotechnological and Applied Clinical Sciences,University of L’Aquila,L’Aquila 67100,Italy

出　　处：《Asian Journal of Andrology》2024年第6期567-568,共2页亚洲男性学杂志（英文版）

摘　　要：Prostate cancer risk stratification relies on several clinical factors. Low-risk patients, characterized by T1–T2a stage, Gleason score (GS) ≤6, and prostate-specific antigen (PSA) <10 ng ml−1, exhibit an excellent prognosis and are suitable for active surveillance (AS). Regular monitoring is essential for these patients, including PSA tests every 3–6 months, annual digital rectal exams (DRE), and prostate biopsies every 6–12 months, followed by less frequent biopsies every 2–5 years. Epstein criteria, which consider GS ≤6, PSA density (PSAD) <0.15 ng ml−2, limited tumor involvement in cores, and absence of high-risk features, help predict pathologic and biochemical relapse-free survival and guide AS management.

关 键 词：patients CLINICAL cancer 

分 类 号：R737.25[医药卫生—肿瘤]